<DOC>
	<DOC>NCT00759655</DOC>
	<brief_summary>This study will be investigating the safety and efficacy of Xyntha (moroctocog alfa (AF-CC)) in male patients less than 6 years old. Annualized bleeding rates and physician / caregiver assessments of responses to treatment will be characterized. FVIII inhibitor levels will be assessed throughout the study.</brief_summary>
	<brief_title>Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age</brief_title>
	<detailed_description>The study was terminated on 22 Sept 2009 due to competition with another Wyeth study for a similar patient population. The decision to terminate the trial was not based on any safety issues.</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male patients less than 6 years of age with moderately severe to severe hemophilia A (FVIII less than or equal to 2%). Treatment history of less than 50 exposure days to prior recombinant or plasmaderived FVIII replacement products. Not receiving treatment for HIV or hepatitis infection, or the patient is on a stable antiviral regimen at the time of enrollment in the study. Presence of any bleeding disorder in addition to hemophilia A. Inhibitor titer of greater than or equal to 5 Bethesda Units (BU) at screening. Treated with immunomodulatory therapy during the screening period Treatment history of more than 5 exposure days (ED) to Xyntha. Known hypersensitivity to hamster protein.</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>hemophilia A</keyword>
	<keyword>Xyntha</keyword>
	<keyword>ReFacto</keyword>
	<keyword>moroctocog alfa</keyword>
	<keyword>bleeding disorder</keyword>
</DOC>